Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 1998

View Archived Issues

MK-886 demonstrates antihyperplastic activity in an animal model of intimal thickening

Alpharma acquires Hoechst's European generic pharmaceutical business

Company Profile: Integra LifeSciences

Company Profile: Sangamo BioSciences

Sepracor: Q1 1998 highlights

Transcell/Intercardia merger complete

Matritech: Q1 1998 highlights

Novartis seek patients for phase III trials of PSC-833

Phase III trials in progress for HMR antipsychotic agent

Merck KGaA, Yamanouchi to codevelop two new cardiovascular drug candidates

QLT PhotoTherapeutics updates shareholders

Evotec awarded German grant for drug discovery

EBV antigens for diagnostic use available for licensing from BioResearch Ireland

Pliva describes coumarin quinolone carboxylic acids for infections and cancer

Transcend Therapeutics announces decision to terminate Procysteine phase III trial

Novel water-soluble azoles for both oral and parenteral treatment of fungal infections

Inhibitors of IL-1beta from ADIR

Pfizer prepares new beta3-adrenoceptor agonists

New SERMs discovered at Lilly and claimed for estrogen-dependent disorders

Lilly develops assay for antitumor agent of natural origin

New light shed on the mechanisms of nicotine addiction

Introgen receives patent protection for p53 gene therapy-chemotherapeutic drug combinations

Promising new TMR data presented at scientific meeting

Novopharm Biotech withdraws IND for phase Ib trial of GPI-2A

HRT more effective than raloxifene in improving heart disease risk factors

CytoMed evaluates CMI-977 in phase I for asthma

FDA grants priority review status for Arava

Phase I clinical trial of novel analgesic to begin in Sweden

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...